Remain bullish about performance overall in FY18: Strides Shasun

Strides Shasun may receive approval for Lovaza generic, which has a market size of around USD 750-800 million in the United Sates and could make upto USD 200 million annually for the company. There has been a lot of buzz around pending application for Omega 3 which is the generic version of Lovaza, Shashank Sinha, MD & Group CEO of Strides Shasun told CNBC-TV18.


Watch More →

A collection of the most-viewed Moneycontrol videos.

Watch and Follow our leading shows